Summary
TESSA® vectors are based on E1/E3-deleted adenovirus type 5 vectors, genetically engineered to self-silence production of adenoviral structural proteins and adenoviral contaminations, but express AAV rep and cap genes stably, and to deliver the AAV GOI transfer genome for efficient AAV manufacture.
TESSA® vectors can only be produced in the presence of doxycycline, while AAV production is carried out in the absence of doxycycline to enable a clean and contaminant-free manufacturing process.
TESSA® is a versatile and robust platform that enables AAV manufacture from two different models. These two models differ in how the gene of interest (GOI) is introduced into the HEK293 cells.